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Purpose: Breast MRI added to mammography increases screening sensitivity for high-risk women but false-positive
(FP) rates are higher and the optimal screening schedule for coordination with mammography is unclear. We compare
rates of FP MRI when studies were performed on two different schedules.
Patients and methods: High-risk women at the University of Vermont who had at least 1 MRI and 1 mammogram
performed within one year between 2004–2012 were eligible for inclusion in this study. Screening was considered
stacked if both studies were performed within 90 days and alternating if studies were 4–8 months apart. False positive
was defined in one of three ways.
Results: 137 women had screening which met inclusion criteria and 371 MRIs were reviewed. The FP rates were similar
for the two schedules when considering BI-RAD 4, 5, 0 or biopsy as a positive test. FP rates were significantly higher for
the stacked schedule (18.2 vs. 10.2%, p = 0.026) when considering BI-RADS 3-4-5-0 as positive test, due to the elevated
rate of BI-RADS 3 assessments among stacked exams.
Conclusion: False positive rates differ based on the type of exam (baseline or subsequent) and definition of positive
but do not differ based on imaging schedule (stacked or alternating); suggesting that women and their providers may
choose the imaging schedule they prefer. This is significant as a randomized clinical trial comparing the two schedules
is not likely to be performed, given the high cost and large number of women needed for such a study.
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The implementation of screening mammography was a
major step in the fight against breast cancer, but several
studies have demonstrated lower sensitivity of mam-
mography in younger women (Kerlikowske et al. 1993)
(Hendrick et al. 1997) and women at increased risk
(Kuhl et al. 2005) (Berg et al. 2008). Adding screening
breast MRI to mammography for women at increased
risk for breast cancer (due to a family history) results in
increased sensitivity and decreased interval cancer rates
(Brekelmans et al. 2001) (Kriege et al. 2001) (Tilanus-
Linthorst et al. 2000) (Kriege et al. 2004) (Weinstein et al.* Correspondence: Marie.Wood@uvm.edu
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in any medium, provided the original work is p2009) (Klijn 2010) (Kuhl et al. 2005) (Warner et al. 2004)
(Leach et al. 2005). However, the specificity of screening
breast MRI is low (79-89%) especially for premeno-
pausal women (Brekelmans et al. 2001) (Kriege et al.
2001) (Tilanus-Linthorst et al. 2000) (Kriege et al.
2004) (Weinstein et al. 2009). This means a high false
positive rate which results in additional imaging, biopsy
and anxiety in this population (Brekelmans et al. 2001)
(Kriege et al. 2001) (Tilanus-Linthorst et al. 2000)
(Kriege et al. 2004) (Weinstein et al. 2009).
In 2007, the American Cancer Society (ACS) published
recommendations for screening breast MRI in addition
to mammography for high risk women which include;
all women with a lifetime risk of more than 20% to 25%
based on family history, women with BRCA mutation,an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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with Li-Fraumeni syndrome and first-degree relatives,
women with Cowden syndrome and first-degree un-
tested relatives, and women who had radiation to chest
wall between ages 10 and 30 (Saslow et al. 2007).
The optimum timing of screening studies (should they
be done at the same time as screening mammography
[“stacked”] or alternating with one study every six months)
has not been addressed. The above mentioned studies
demonstrating the increased sensitivity when MRI is
added to mammogram specified that imaging studies were
done within a short period of time (on the same day or
less than 90 days apart). There have been no studies com-
paring the two screening schedules directly. Identifying
the optimal screening schedule may reduce the false posi-
tive rates and reduce unnecessary biopsies and imaging.
The current study was undertaken to compare the false
positive rates for screening breast MRI when imaging is
done at the same time each year (a stacked schedule)
compared to an every six month imaging (an alternating)
schedule.
Patients and methods
Women enrolled in an Institutional Review Board (IRB)
approved prospective study of women at moderate and
high risk for breast cancer between 2004 and 2012 at the
University of Vermont were the subject of this current
study. To be eligible to participate in the IRB approved
database participants must have an increased risk for de-
veloping breast cancer. Patients are identified as having
an increased risk for developing breast cancer if they
meet any one of the following criteria: A strong family
history of breast (male or female) and/or ovarian cancer.
Strong family history is defined as one of the following:
a. Two or more first-degree relatives with breast cancer
or ovarian cancer. b. One first-degree relative and two
or more second- or third degree relatives with breast
cancer. c. One first-degree relative with breast cancer or
ovarian cancer before the age of 50 years. d. One first-
degree relative with breast cancer and one or more rela-
tives with ovarian cancer. e. Two second- or third-degree
relatives with breast cancer and one or more with ovarian
cancer. f. One second- or third-degree relative with breast
cancer and two or more with ovarian cancer. g. Three or
more second- or third-degree relatives with breast can-
cer. h. One first-degree relative with bilateral breast
cancer. Individuals with a known genetic abnormality
of a breast cancer causing gene in themselves or a fam-
ily member. Individuals with a prior breast biopsy
showing atypical ductal hyperplasia or lobular neoplasia
(atypical lobular hyperplasia or lobular carcinoma in-
situ). Individuals with a Gail Model breast cancer risk
of greater than or equal to 1.66% over the next 5 years
or greater than 20% lifetime risk.To be included in the current study women must have
had at least 1 screening breast MRI and 1 mammogram
performed within 1 year. Women were excluded if they
had a personal history of invasive breast cancer, had a
diagnostic screening breast MRI (i.e., an MRI done to
evaluate suspicious lesions on mammography or clinical
breast examination, or MRI done as part of work-up for
breast cancer) or were using chemoprevention. Medical
records were abstracted for clinical, radiological, and bi-
opsy data. One cycle of surveillance was defined as 1
MRI and 1 mammogram done within 1 year. Screening
was considered stacked if both studies were performed
within 90 days and alternating if studies were 4–8
months apart. Three definitions of a false-positive MRI
were considered: 1) MRI result of BI-RADS 4, 5, 0 with
no cancer diagnosis within 365 days; 2) BI-RADS 3, 4, 5,
0 with no cancer diagnosis within 365 days; and 3) be-
nign breast biopsy after an MRI-based recommendation.
Dynamic contrast enhanced MRI was performed ac-
cording to standard techniques (which varied over the
time course of the study) and interpreted by breast im-
aging radiologists with 1–12 years’ experience interpret-
ing breast MRI. The original clinical reports were used
in this study. The images were not re-analyzed for re-
search purposes.Statistics
The analyses were restricted to the 371 MRIs among
137 women which met the above inclusion criteria. Chi-
square tests and Fisher’s exact tests were used to com-
pare differences in assessments and false-positive rates
between stacked and alternating MRI screens. All statis-
tical analyses were performed using SAS Statistical Soft-
ware (Version 9.2; SAS Institute, Inc., Cary, North
Carolina).Results
The records of 599 women at increased risk of develop-
ing breast cancer and enrolled in the parent database at
the University of Vermont from May 1st, 2004 to March
31st, 2012 were reviewed. 440 women did not have a
breast MRI as part of their screening, 16 women who
had breast MRI performed to evaluate mammographic
findings were excluded; an additional 6 women were ex-
cluded because they did not have an MRI and mammo-
gram performed within one year. Therefore, 137 women
met the inclusion criteria and are the subject of this ana-
lysis. See Figure 1 for a consort diagram of study partici-
pants. The mean age of women at the time of initial
screening breast MRI was 45.8; 78.8% were premeno-
pausal. High risk was attributed to strong family history
of breast cancer in 87.6%, BRCA mutation in 18.3%, and
prior atypical biopsy in 13.1%. The median number of
Figure 1 Consort diagram for population screened.
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lines the characteristics of the participants.
Forty-five women had all screening cycles done on a
stacked schedule, 52 women had all cycles done on an
alternating schedule, while 40 women had cycles that
were mixed with some on a stacked schedule and others
on an alternating schedule. 371 screening breast MRIs
were reviewed; 165 performed on a stacked and 206 on
an alternating schedule. Table 2 reveals the BI-RADS in-
terpretation for MRIs performed on each schedule.
There were significantly more BI-RADS category 3 inter-









Family history 120 (87.6%)
BRCA positive 25 (18.2%)
Biopsy with atypia or lobular neoplasia 18 (13.1%)
Prior chest irradiation 2 (1.5%)
*Note that individual women could have multiple reasons for screening.(9.7 vs. 2.9%, p = 0.006). The likelihood of BI-RADS cat-
egory 4, 5, or 0 interpretation was not significantly dif-
ferent between the two groups (9.7 vs. 8.3%, p = 0.627).
In addition there were fewer BI-RADS category 1 or 2
interpretations for MRIs performed on a stacked sched-
ule (80.6 vs 88.8%, p = 0.027).
The false positive rate was first calculated for MRIs
with BI-RADS 4,5,0 interpretations demonstrating a non-
significant difference between screening on a stacked or
alternating schedule (8.5 vs 7.3% respectively, p = 0.668)
(Table 3). Defining the false-positive rate for MRIs as BI-
RADS 3, 4, 5, 0 interpretation revealed a significant differ-
ence between the two screening schedules with 18.2% of
MRIs performed on the stacked schedule having a false-
positive study compared to 10.2% of MRIs performed on
the alternating schedule (p = 0.026). Taking into accountTable 2 BI-RADS interpretation according to screening
schedule
Interpretation Stacked (n = 165) Alternating (n = 206) P
valueN (%) [95% CI] N (%) [95% CI]
BI-RADS 1 or 2 133 (80.6%) 183 (88.8%) 0.027
[73.9, 86.0] [83.8, 92.5]
BI-RADS 3 16 (9.7%) 6 (2.9%) 0.006
[6.0, 15.3] [1.2, 6.4]
BI-RADS 4, 5, 0 16 (9.7%) 17 (8.3%) 0.627
[6.0, 15.3] [5.1, 12.9]
Table 3 False positive rates according to schedule
Overall Stacked Alternating p
value(n = 371) (n = 165) (n = 206)
BI-RADS 3* 22 (5.9%) 16 (9.7%) 6 (2.9%) 0.006
[3.9, 8.9] [6.0, 15.3] [1.2, 6.4]
BI-RADS 4, 5, 0 29 (7.8%) 14 (8.5%) 15 (7.3%) 0.668
[5.5, 11.0] [5.0, 13.8] [4.4, 11.8]
BI-RADS 3, 4, 5, 0 51 (13.7%) 30 (18.2%) 21 (10.2%) 0.026
[10.6, 17.6] [13.0, 24.8] [6.7, 15.1]
BI-RADS 3, 4, 5, 0 31 (24.6%) 20 (27.4%) 11 (20.8%) 0.393
For baseline MRI [17.9, 32.8] [18.4, 38.6] [11.8, 33.6]
BI-RADS 3, 4, 5, 0 20 (8.2%) 10 (10.9%) 10 (6.5%) 0.230
For subsequent MRI [5.3, 12.3] [5.8, 19.0] [3.5, 11.8]
Benign biopsy 22 (5.9%) 10 (6.1%) 12 (5.8%) 0.92
[3.9, 8.9] [3.2, 10.9] [3.3, 10.0]
*p value compares stacked to alternating schedule.
**Numbers in parentheses are percentages, and numbers in square brackets
are the 95% Agresti-Coull confidence intervals for the percentage.
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nated the statistical significance. However stacked exams
(both baseline and subsequent) did have a higher rate of
false-positive BI-RADS 3, 4, 5, 0 exams compared to alter-
nating exams.
We then considered false-positive according to benign
biopsy rates. A total of 34 biopsies were performed in
the entire cohort with 25 biopsies based on MRI inter-
pretations. The false-positive rate based on a benign bi-
opsy for the entire group was 5.9% (22/371) a rate of
6.1% (10/165) for the stacked group and 5.8% (12/206)
for the alternating group. There was not a significant dif-
ference between false-positive rates based on having a
benign biopsy for the stacked compared to alternating
group (p = 0.92).
Four breast cancers were detected in 137 women in-
cluded in this cohort. Three were identified by MRI (1 on
a stacked schedule and 2 on an alternating schedule).
There was 1 interval cancer in this cohort. Table 4 demon-
strates the characteristics of the cancers identified. No
cancers were identified in women within 1 year of having
a BI-RADS 3 category MRI.Table 4 Characteristics of breast cancers diagnosed in cohort





Abbreviations: MD =moderately differentiated, PD = poorly differentiated, IDC = infi
ER = estrogen receptor, PR = progesterone receptor.Discussion
In this retrospective evaluation of a prospectively gath-
ered cohort we have shown similar rates of false positive
studies regardless of the screening schedule or definition
of a positive study. To our knowledge, this is one of the
first studies to compare the two styles of screening in a
prospectively gathered cohort and one of the largest series
to examine the alternating schedule of mammogram and
screening breast MRI. Le-Petross et al. reported their insti-
tutional practice of alternating studies and found a sensitiv-
ity of 92% and a specificity of 79%; similar to published
series with studies performed annually (Brekelmans et al.
2001) (Kriege et al. 2001) (Tilanus-Linthorst et al. 2000)
(Kriege et al. 2004) (Weinstein et al. 2009) (Klijn 2010)
(Kuhl et al. 2005) (Warner et al. 2004) (Leach et al. 2005;
Le-Petross et al. 2011). While their study suggests that im-
aging performed on an alternating schedule has similar
sensitivity and specificity to imaging performed on a
stacked schedule, they did not compare the two strat-
egies. One additional study suggests that alternating im-
agining is a more cost efficient strategy, especially for
BRCA1 carriers, largely related to the high incidence of
cancer (Cott Chubiz et al. 2013) (Lowry et al. 2012).
In our cohort false-positive rates were influenced by
both the type of examination and the definition of a
positive study. We observed a higher overall false posi-
tive rate for baseline screening MRI compared to subse-
quent examination (24.8% vs 9.5%) as highlighted in
Table 3. Higher false-positive rates for baseline com-
pared to subsequent mammograms have been reported
(Frankel et al. 1995) (Burnside et al. 2002) (Callaway
et al. 1997). Only one study has examined this issue for
screening MRI (Abramovici & Mainiero 2011). Using
data from the Dutch MRI Screening (MRISC) study the
false positive rate for the baseline screening breast MRI
was 14% which decreased to 8.2% with subsequent
rounds of screening. We did not find a significant differ-
ence between false-positive rates for baseline or subse-
quent examinations based on schedule.
We did observe a significant difference in false-positive
rates depending on the definition of a positive study (BI-
RADS 4, 5, 0 vs BI-RADS 3, 4, 5, 0 or biopsy). We found
the highest false-positive rate when considering BI-RADSBiopsy result Breast cancer risk factor
0.8 cm MD IDC, LN -, ER/PR+, HER 2- Hx of LCIS
0.7 cm MD ILC, LN-, ER/PR +, HER 2- BRCA 2 carrier
0.6 cm MD ILC, LN-, ER+, PR+ BRCA 2 carrier
2.4 cm PD IDC, LN+, ER+, PR-, HER 2 - BRCA 1 carrier
ltrating ductal carcinoma, ILC = infiltrating lobular carcinoma, LN = lymph node,
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of false-positive studies for BI-RADS 4, 5, 0 (7.8%) and for
benign biopsy (5.9%). The higher rate when calling BI-
RADS 3, 4, 5, 0 positive can be explained by BI-RADS 3
interpretations. In our cohort there were no cancers iden-
tified within one year of any BI-RADS 3 MRI. Others have
shown similarly high rates of false positive screening
breast MRI when including BI-RADS 3 interpretations as
positive, with a range between 6.3 – 27% in published
studies (Bahrs et al. 2014) (Eby et al. 2009) (Liberman
et al. 2003) (Weinstein et al. 2010) (Eby et al. 2007)
(Hauth et al. 2010) (Kuhl et al. 2005) (Rosen et al. 2002)
(Barr et al. 2013). The high rate of BI-RADS 3 lesions and
low likelihood of malignancy associated with a BI-RADS 3
lesions for any breast screening modality (MRI, mammo-
gram or ultrasound) has prompted some to suggest that
short-interval follow-up may not be needed for this group
(Bahrs et al. 2014) (Barr et al. 2013) (Varas et al. 2002)
(Vizcaino et al. 2001).
The number of cancers identified in our population is
quite small, likely due to the broader definition of “high
risk” and short follow-up time. Three of the four cancers
were identified by screening and these were all lymph
node negative and less than 1 cm (Table 4). There was
one interval cancer in a BRCA1 carrier which was lymph
node positive and >2 cm. This low rate of interval cancers
is similar to other studies combining screening breast
MRI with annual mammography (Kriege et al. 2004)
(Warner et al. 2004) (Leach et al. 2005) (Kuhl et al. 2005)
(Sardanelli et al. 2011). Similar to Warner et al. we have
shown that screening with MRI is associated with identifi-
cation of lower risk cancers (Warner et al. 2011) (Gareth
et al. 2014).
This study has weaknesses that must be considered.
Women in this study were not randomized to a screening
schedule and there is likely some selection bias to the
choices made for screening schedule. The cohort is het-
erogeneous with respect to breast cancer risk; including
women with BRCA mutations, women with strong family
histories and women who had a biopsy showing atypia.
Despite these weaknesses this study has several strengths.
This is the largest cohort to date reporting screening on
different schedules. Le-Petross et al. studied 73 women
with BRCA1 and BRCA2 mutations who were getting
every 6 month (alternating) screening only (Le-Petross
et al. 2011). In our cohort of high risk women the decision
of which schedule to adhere to (alternating or stacked)
was made by the provider and patient, making it similar
to a real –world experience. The majority of women (71%)
kept to the chosen schedule through multiple rounds of
screening; despite the fact that this population is young
and largely (79%) premenopausal.
In conclusion, we have shown that the false-positive
rates are similar for studies performed on either a stackedor alternating schedules regardless of the definition of a
false-positive study. This finding and information from
prior studies (Le-Petross et al. 2011) showing similar sen-
sitivity for alternating schedules, suggests that high risk
women and their providers may choose the schedule they
prefer when screening with annual MRI and mammo-
gram. This is important as there is not likely to be a ran-
domized clinical trial comparing the two schedules given
the high cost and large number of women needed for such
a study.
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